to investigate the pharmacodynamics of tetrabenazine [ 1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-2-h-benzo ( a ) quinol izine-2- one ; 1 ] , the drug of choice in the control of huntington 's chorea and tardive dyskinesia , and its major metabolite , dihydrotetrabenazine ( 2 ) , ip doses of 3 mg/kg of the drug and the metabolite were administered to rats .
C0039623
tetrabenazine
C0020179
huntington 's chorea